Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug

Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd., “Ribo”, is pleased to announce the successful completion of patient recruitment for the Phase 2a clinical trial, utilizing the world’s first and most advanced hemostasis sparing anti-thrombotic siRNA drug, targeting FXI, RBD4059. In less than 10 months since CTA approval of the Phase 2 trial, the […]